Retour
54
61
1
28
39
Également cotée sous
OLYMY
OTC
Fourchette du Jour
8,61 €
9,29 €
Fourchette 52 Semaines
8,00 €
14,00 €
Volume
15
Moyenne 50J / 200J
10,83 €
/
12,07 €
Clôture Précédente
8,61 €
Quick Summary
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (631 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 0,1 | 0,3 |
| P/B | 0,0 | 3,0 |
| ROE % | 15,6 | 3,7 |
| Net Margin % | 11,8 | 3,8 |
| Rev Growth 5Y % | 8,1 | 10,0 |
| D/E | 0,3 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2030 |
126,93 €
124,00 € – 131,20 €
|
1,16T | 1 |
| FY2029 |
119,14 €
116,39 € – 123,15 €
|
1,12T | 1 |
| FY2028 |
108,13 €
105,63 € – 111,77 €
|
1,09T | 1 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-13 | 23,08 € | 0,08 € | -99,6% |
| 2025-05-13 | 0,16 € | 0,25 € | +60,7% |
| 2025-02-12 | 0,22 € | 0,15 € | -31,1% |
| 2024-11-08 | 0,22 € | 0,20 € | -8,8% |
| 2024-08-07 | 0,09 € | 0,08 € | -13,9% |
| 2024-05-10 | 0,11 € | 0,04 € | -60,8% |
| 2024-02-14 | 0,16 € | 0,11 € | -30,2% |
| 2023-09-30 | 0,17 € | -0,13 € | -177,3% |
Dividend History
Yield
0,01%
Payout Ratio
N/A
Growth (3Y)
N/A
Growth (5Y)
N/A
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 31, 2026 | Jun 01, 2026 | 0,19 € | 2,21% |
| Mar 31, 2025 | Jun 05, 2025 | 0,13 € | 0,96% |
| Mar 28, 2024 | Jun 05, 2024 | 0,12 € | 0,82% |
| Mar 30, 2023 | Jun 06, 2023 | 0,12 € | 0,70% |
| Mar 30, 2022 | Jun 03, 2022 | 0,11 € | 0,60% |
| Mar 30, 2021 | Jun 03, 2021 | 0,11 € | 0,49% |
| May 28, 2020 | Jul 31, 2020 | 0,09 € | 0,67% |
| Mar 27, 2019 | Jun 26, 2019 | 0,27 € | 0,62% |
| Mar 28, 2018 | Jun 27, 2018 | 0,26 € | 2,73% |
| Mar 29, 2017 | Jun 29, 2017 | 0,25 € | 0,72% |
| Mar 29, 2016 | Jun 29, 2016 | 0,15 € | 1,54% |
| Mar 27, 2015 | Jun 29, 2015 | 0,08 € | 0,22% |
| Mar 29, 2011 | Jun 30, 2011 | 0,18 € | 1,33% |
| Sep 28, 2010 | Dec 03, 2010 | 0,18 € | 1,39% |
| Mar 29, 2010 | Jun 30, 2010 | 0,16 € | 1,06% |
| Sep 25, 2009 | Dec 04, 2009 | 0,17 € | 0,63% |
| Sep 25, 2008 | Dec 05, 2008 | 0,19 € | 1,47% |
| Mar 26, 2008 | Jun 30, 2008 | 0,20 € | 1,42% |
| Sep 25, 2007 | Dec 07, 2007 | 0,17 € | 1,37% |
| Mar 27, 2007 | Jun 29, 2007 | 0,20 € | 0,88% |
Points Clés
Revenue grew 8,09% annually over 5 years — modest growth
Earnings declined -51,41% over the past year
ROE of 15,62% — decent returns on equity
Debt/Equity of 0,30 — conservative balance sheet
Generating 125,25B in free cash flow
P/E of 0,08 — trading at a low valuation
Croissance
Revenue Growth (5Y)
8,09%
Revenue (1Y)6,53%
Earnings (1Y)-51,41%
FCF Growth (3Y)112,01%
Qualité
Return on Equity
15,62%
ROIC12,42%
Net Margin11,82%
Op. Margin16,29%
Sécurité
Debt / Equity
0,30
Current Ratio1,60
Interest Coverage23,75
Valorisation
P/E Ratio
0,08
Forward P/EN/A
P/B Ratio0,01
EV/EBITDA-0,09
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6,53% | Revenue Growth (3Y) | 6,34% |
| Earnings Growth (1Y) | -51,41% | Earnings Growth (3Y) | -9,35% |
| Revenue Growth (5Y) | 8,09% | Earnings Growth (5Y) | 73,80% |
| Profitability | |||
| Revenue (TTM) | 997,33B | Net Income (TTM) | 117,86B |
| ROE | 15,62% | ROA | 8,23% |
| Gross Margin | 68,55% | Operating Margin | 16,29% |
| Net Margin | 11,82% | Free Cash Flow (TTM) | 125,25B |
| ROIC | 12,42% | FCF Growth (3Y) | 112,01% |
| Safety | |||
| Debt / Equity | 0,30 | Current Ratio | 1,60 |
| Interest Coverage | 23,75 | ||
| Dividends | |||
| Dividend Yield | 0,01% | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 0,08 | Forward P/E | N/A |
| P/B Ratio | 0,01 | P/S Ratio | 0,01 |
| PEG Ratio | 0,05 | Forward PEG | N/A |
| EV/EBITDA | -0,09 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 1321,21% | ||
| Market Cap | 9,48B | Enterprise Value | -13,95B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 997,33B | 936,21B | 881,92B | 868,87B | 730,54B |
| Net Income | 117,86B | 242,57B | 143,43B | 115,74B | 12,92B |
| EPS (Diluted) | 102,80 | 21,88 | 108,65 | 90,17 | 51,00 |
| Gross Profit | 683,70B | 625,12B | 562,70B | 475,99B | 427,99B |
| Operating Income | 162,46B | 151,89B | 186,61B | 166,30B | 102,50B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,43T | 1,53T | 1,51T | 1,36T | 1,18T |
| Total Liabilities | 681,09B | 777,03B | 865,32B | 844,60B | 785,55B |
| Shareholders' Equity | 751,73B | 757,19B | 640,09B | 510,17B | 394,33B |
| Total Debt | 229,10B | 299,62B | 340,06B | 386,13B | 355,26B |
| Cash & Equivalents | 252,53B | 340,93B | 164,55B | 294,58B | 173,28B |
| Current Assets | 679,44B | 800,34B | 726,36B | 694,61B | 580,07B |
| Current Liabilities | 425,36B | 431,70B | 461,89B | 376,25B | 328,39B |
Scores de Stratégies
This stock passed the criteria for 5 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#330 of 1052
#138 of 827
#661 of 670
#360 of 709
Custom
Balanced Risk
#114 of 151
Activité Récente
Entré
Cash Flow Compounder
Mar 24, 2026
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Contrarian Investing (David Dreman)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026
Entré
Balanced Risk
Mar 24, 2026